Open AccessWpływ reformy zdrowotnej w Stanach Zjednoczonych ObamaCare na biznes farmaceutyczny
Author(s) -
Łukasz Jasiński,
Marta Makowska
Publication year - 2016
Publication title -
ekonomia/acta universitatis wratislaviensis. ekonomia
Language(s) - English
Resource type - Journals
eISSN - 2658-1310
pISSN - 2084-4093
DOI - 10.19195/2084-4093.22.4.3
Subject(s) - transparency (behavior) , incentive , pharmaceutical industry , business , medical prescription , health care , health insurance , healthcare industry , point (geometry) , accounting , public economics , economics , pharmacology , political science , medicine , market economy , economic growth , law , geometry , mathematics
Impact of the Healthcare Reform in the United States ObamaCare on the Pharmaceutical Business ObamaCare changes have different influence on diverse healthcare business. Pharmaceutical industry seems to gain on this reform unlike the insurance business. In this article we briefly present the main positive and negative effects of health reform in the US. Then, we point to the impact of ObamaCare on profits, costs and activities of pharmaceutical companies. We discuss changes such as: increase in sales of prescription drugs; new rules of registration of generic drugs; novel tax on sales of original drugs; incentives for pharma to put more attention to specific fields in R&D; bigger transparency in relations between physicians and pharma industry.